MANGOCEUTICALS Files 8-K on Jan 18 Event; Nasdaq Listing Confirmed
Ticker: MGRX · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $0.30, $160,000, $0 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, corporate-governance, exchange-listing
TL;DR
**MGRX filed a routine 8-K, confirming its Nasdaq listing and compliance.**
AI Summary
MANGOCEUTICALS, INC. (MGRX) filed an 8-K on January 23, 2024, reporting an 'Other Event' that occurred on January 18, 2024. This filing primarily serves to update the public record regarding the company's status and its common stock, which is registered on The Nasdaq Stock Market LLC (Nasdaq Capital Market) under the trading symbol MGRX. For investors, this filing is a routine update, confirming the company's continued compliance and listing on Nasdaq, which is important for liquidity and visibility.
Why It Matters
This filing confirms MANGOCEUTICALS' continued listing on the Nasdaq Capital Market, which is crucial for the stock's trading liquidity and investor confidence. It's a standard compliance update, not indicating any major operational changes.
Risk Assessment
Risk Level: low — This 8-K is a standard compliance filing and does not introduce new risks or significant changes to the company's operations or financial health.
Analyst Insight
Investors should view this as a routine compliance filing, indicating no immediate need for action. It confirms the company's ongoing listing on Nasdaq, which is a positive for market access and liquidity, but doesn't suggest any new catalysts or risks.
Key Numbers
- $0.0001 — Par Value Per Share (The stated par value of MANGOCEUTICALS, INC. Common Stock.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — the registrant filing the 8-K
- Nasdaq Stock Market LLC (company) — the exchange where MGRX common stock is registered
- MGRX (company) — the trading symbol for MANGOCEUTICALS, INC. common stock
- January 18, 2024 (date) — the date of the earliest event reported in the 8-K
- January 23, 2024 (date) — the filing date of the 8-K
- $0.0001 (dollar_amount) — par value per share of common stock
FAQ
What is the purpose of this 8-K filing by MANGOCEUTICALS, INC.?
This 8-K filing, dated January 23, 2024, reports an 'Other Event' that occurred on January 18, 2024, and serves as a current report to update the public record, confirming the company's status and its common stock listing on The Nasdaq Stock Market LLC.
On which stock exchange is MANGOCEUTICALS, INC. common stock registered?
MANGOCEUTICALS, INC. common stock, with a $0.0001 par value per share, is registered on The Nasdaq Stock Market LLC (Nasdaq Capital Market) under the trading symbol MGRX, as stated in the filing.
What is the trading symbol for MANGOCEUTICALS, INC. common stock?
The trading symbol for MANGOCEUTICALS, INC. common stock is MGRX, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section of the filing.
What was the 'Date of Earliest Event Reported' in this 8-K?
The 'Date of Report (Date of Earliest Event Reported)' for this 8-K filing was January 18, 2024.
What is the par value of MANGOCEUTICALS, INC. Common Stock?
The par value of MANGOCEUTICALS, INC. Common Stock is $0.0001 per share, as specified in the filing under 'Title of each class'.
Filing Stats: 807 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2024-01-22 19:42:43
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
- $0.30 — rs at a purchase price to the public of $0.30 per share and also granted to the Under
- $160,000 — scounts and expenses, was approximately $160,000. Inclusive of the full exercise of the
- $0 — ts common stock at an exercise price of $0.375, subject to adjustments (the " Warr
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex4-1.htm (EX-4.1) — 97KB
- 0001493152-24-003338.txt ( ) — 329KB
- mgrx-20240118.xsd (EX-101.SCH) — 3KB
- mgrx-20240118_lab.xml (EX-101.LAB) — 33KB
- mgrx-20240118_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: January 22, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer